Endothelial integrity, soluble adhesion molecules and platelet markers in Type 1 diabetes mellitus

Diabetic Medicine

Volumn 15, Issue 8, 1998, Pages 634-642

  Blann, A D ^a   Lip, G Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Endothelial cells; Platelets; Soluble adhesion molecules; Type 1 diabetes mellitus

Indexed keywords

CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN; INTERCELLULAR ADHESION MOLECULE 1; THROMBOMODULIN; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; ENDOTHELIUM INJURY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK; STROKE; THROMBOCYTE DYSFUNCTION; VASCULAR ENDOTHELIUM;

ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PLATELETS; CELL ADHESION MOLECULES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; E-SELECTIN; ENDOTHELIUM, VASCULAR; HUMANS; THROMBOMODULIN; VON WILLEBRAND FACTOR;

EID: 0031847174     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199808)15:8<634::AID-DIA636>3.0.CO;2-8     Document Type: Review

References (108)

1. Steiner G. Diabetes and atherosclerosis. Diabetes 1981; 30 (suppl 2): 1-7.
2. Morrish NJ, Stevens LK, Head J, Jarrett RJ, Keen H. A prospective study of mortality among middle aged diabetic patients (the London cohort of the WHO multinational study of vascular disease in diabetics). 1: Causes and death rates. Diabetologia 1990; 33: 538-541.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
4. Colwell JA, Winocour PD, Halushka PV. Do platelets have anything to do with diabetic microvascular diseases? Diabetes 1983; 32 (suppl 2): 14-19.
5. Vukovich TC, Schernthaner G, Knobi PN, Hay U. The effect of near normoglycaemic control on plasma factor VIII/von Willebrand factor and fibrin degredation products in insulin-dependent diabetic patients. J Clin Endocrinol Metabol 1989; 69: 84-89.
6. Carter AM, Grant P. Vascular homeostasis, adhesion molecules and macrovascular disease in non-insulin dependent diabetes mellitus. Diabetic Med 1997; 14: 423-432.
7. Schneider DJ, Sobel BE. Determinants of coronary vascular disease in patients with type II diabetes mellitus and their therapeutic complications. Clin Cardiol 1997; 20: 433-440.
8. Davies MG, Hagen P-O. The vascular endothelium. A new horizon. Annals Surg 1993; 218: 593-609.
9. Poston L, Taylor PD. Endothelium-mediated vascular function in insulin dependent diabetes mellitus. Clin Sci 1995; 88: 245-255.
10. Luscher TF. The endothelium and cardiovascular disease-a complex relation. N Engl J Med 1994; 330: 1081-1083.
11. Pearson JD. Markers of endothelial perturbation and damage. Br J Rheumatol 1993; 32: 651-652.
12. Boneu B, Abbal M, Plante J, Bierme R. Factor VIII complex and endothelial damage. Lancet 1975; 1: 1430.
13. Mordes DB, Lazarchick J, Colwell JA, Sens DA. Elevated glucose concentrations increase factor VIIIR:Ag levels in human umbilical vein endothelial cells. Diabetes 1983; 32: 876-878.
14. Greaves M, Pickering C, Knight G, Boulton AJM, Ball J, Ward JD, Preston FE. Changes in the factor VIII complex in diabetic ketoacidosis: evidence of endothelial cell damage? Diabetologia 1987; 30: 160-165.
15. Leurs PB, van Oerle R, Hamulyak K, Wolffenbuttel. Tissue factor pathway inhibitor activity in patients with IDDM. Diabetes 1995; 44: 80-84.
16. Porta N, Townsend C, Clover GM, Nanson M, Alderson AR, McCraw A, Kohner EM. Evidence for functional endothelial cell damage in early diabetic retinopathy. Diabetologia 1981; 20: 597-601.
17. Jensen T. Increased plasma concentration of von Willebrand factor in insulin dependent diabetics with incipient nephropathy. Br Med J 1989; 298: 27-28.
18. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet 1989; 1: 461-463.
19. Stehouwer CDA, Stroes ESG, Hackeng WHL, Mulder PGH, den Ottolander GJH. von Willebrand factor and development of diabetic nephropathy in IDDM. Diabetes 1991; 40: 971-976.
20. Knobl P, Schernthaner G, Schnack C, Pietschmann P, Griesmacher A, Prager R, Muller M. Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non-insulin dependent) diabetic patients. Diabetologia 1993; 36: 1045-1050.
21. Zimmermann J, Schramm L, Waner C, Mulzer E, Henrich HA, Langer R, Heidreder E. Hemorheology, plasma protein composition and von Willebrand factor in type 1 diabetic nephropathy. Clin Nephrol 1996; 46: 230-236.
22. Myrup B, Mathiesen ER, Ronn B, Deckert T. Endothelial function and serum lipids in the course of developing microalbuminuria in insulin dependent diabetes mellitus. Diabetes Res 1994; 26: 33-39.
23. Yokoyama H, Jensen JS, Myrup B, Mathiesen ER, Ronn B, Deckert T. Raised serum sialic acid concentration precedes onset of microalbuminuria in IDDM. A 10-year follow-up study. Diabetes Care 1996; 19: 435-450.
24. Knobl P, Schernthaner G, Schnack C, Pietschmann P, Griesmascher A, Prager R, Muller M. Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non-insulin dependent) diabetic patients. Diabetologia 1993; 36: 1045-1050.
25. Plater ME, Ford I, Dent MT, Preston FE, Ward JD. Elevated von Willebrand factor antigen predicts deterioration in diabetic peripheral nerve function. Diabetologia 1996; 39: 336-343.
26. Stehouwer CDA, Zellenrath P, Polak BCP, Baarsma GS, Nauta JJP, Donker AJM, den Ottolander GJH. Von Willebrand factor and early diabetic retinopathy: no evidence for a relationship in patients with type 1 (insulin dependent) diabetes mellitus and normal urinary albumin excretion. Diabetologia 1992; 35: 555-559.
27. Stehouwer CDA. Is the increase in plasma von Willebrand factor concentrations in diabetes mellitus related to insulin levels? Thromb Haemostas 1994; 71: 398-399.
28. Yaqoob M, Patrick AW, McClelland P, Stevenson A, Mason H, White MC, Bell GM. Relationship between markers of endothelial dysfunction, oxidant injury and tubular damage in patients with insulin dependent diabetes mellitus. Clin Sci 1993; 85: 557-562.
29. Stehouwer CDA, Fischer HRA, van Kuijk AWR, Polak BCP, Donker AJM. Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes 1995; 44: 561-564.
30. Earle KA, Mishra M, Morocutti A, Barnes D, Stephens E, Chambers J, Viberti GC. Microalbuminuria as a marker of silent moycardial ischaemia in IDDM patients. Diabeto- logia 1996; 39: 854-856.
31. Stehouwer CDA, Donker AJM. Urinary albumin excretion and cardiovascular disease risk in diabetes mellitus: is endothelial dysfunction the missing link? J Nephrol 1993; 6: 72-92.
32. Deckert T, Yokoyama H, Mathiesen E, Ronn B, Jensen T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen JS. Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes. Br Med J 1996; 312: 871-874.
33. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-355.
34. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo J, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. New Engl J Med 1995; 332: 635-641.
35. Jones SL, Close CF, Mattock MB, Jarrett RJ, Keen H, Viberti GC. Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria. Br Med J 1989; 298: 487-490.
36. Boffa MC. Considering cellular thrombomodulin distribution and its modulating factors can facilitate the use of plasma thrombomodulin as a reliable endothelial marker. Haemostasis 1996; 26 (suppl 4): 233-243.
37. Galajda P, Martinka E, Mokan M, Kubisz P. Endothelial cell markers in diabetes mellitus. Thromb Res 1997; 85: 63-65.
38. Iwashima Y, Sato T, Watanabe K, Ooshima E, Hiraishi S, Ishii H, Kazama M, Makino I. Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy. Diabetes 1990; 39: 983-988.
39. Gruden G, Pagano G, Romagnoli R, Frezet D, Olivetti C, Cavallo-Perin P. Thrombomodulin levels in insulin dependent diabetic patients with microalbuminuria. Diabetic Med 1995; 12: 258-260.
40. Gabat S, Keller C, Kempe HP, Amiral J, Ziegler R, Ritz E, et al. Plasma thrombomodulin: a marker for microvascular complications in diabetes mellitus. Vasa 1996; 25: 233-241.
41. Leurs PB, van Oerle R, Hamulyak K, Wolffenbuttel BHR. Tissue factor pathway inhibitor activity in patients with IDDM. Diabetes 1995; 44: 80-84.
42. Seigneur M, Dufourcq P, Gin H, Delafaye C, Amiral J, Pruvost A, Boisseau MR. Plasma thrombomodulin levels increase with the severity of the diabetic retinopathy. Blood Coag Fibrin 1994; 5: 845-846.
43. McLaren M, Elhadd TA, Bancroft A, Connacher M, Belch JJF. Markers of endothelial cell damage and oxidative stress in juvenile diabetics (Abstract). Blood Coag Fibrin 1997; 8: 480.
44. Newman W, Beall LD, Carson CW, Hunder GG, Graben N, Randhawa ZI, et al. Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. J Immunol 1993; 150: 644-654.
45. Gearing AJH, Hemingway I, Pigott R, Hughes J, Rees AJ, Cashman SJ. Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1; pathological significance. Annals NY Acad Sci 1992; 667: 324-331.
46. Steiner M, Reinhardt KM, Krammer B, Ernst B, Blann AD. Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemostas 1994; 72: 979-984.
47. Cominiacini L, Pasini AF, Garbin U, Davoli A, De Santis A, Campagnola M et al. Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia 1995; 38:1122-1124.
48. Fasching P, Veitl M, Rohac M, Streli C, Schneider B, Waldhausl W, Wagner OF. Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin dependent diabetes mellitus. J Clin Endocrin Metabol 1996; 81: 4313-4317.
49. Blann AD, McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemostas 1994; 72: 151-154.
50. Kirk G, Elhadd TA, Robb R, McLaren M, Stonebridge P, Belch JJF. Soluble E-selectin levels in diabetic patients with severe peripheral arterial occlusive disease (Abstract). Blood Coag Fibrin. 1996; 7: 2.
51. Kirk G, Elhadd T, McLaren M, Greene S, Belch JJF. Dietary essential fatty acid supplementation in young patients with insulin dependent diabetes mellitus attenuates endothelial activation and/or damage (Abstract). Blood Coag Fibrin 1997; 8: 467.
52. Lerman A, Edwards BS, Hallett JK, Heublein DM, Sandberg SM, Burnett JC. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. New Engl J Med 1991; 325: 997-1001.
53. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990; 33: 306-310.
54. Collier A, Leach JP, McLennan A, Jardine A, Morton JJ, Small M. Plasma endothelin-like immunoreactive levels in IDDM patients with microalbuminuria. Diabetes Care 1992; 15: 1038-1040.
55. Kawamura M, Ohgawara H, Naruse M, Suzuki N, Iwasaki N, Naruse K, et al. Increased plasma endothelin in NIDDM patients with retinopathy. Diabetes Care 1992; 15: 1396-1397.
56. Malamitisi-Puchner A, Economou E, Katsouyanni K, Krachaliou F, Delis D, Bartsocas CS. Endothelin 1-21 plasma concentrations in children and adolescents with IDDM. J Ped Endocrin Metabol 1996; 9: 463-468.
57. Smulders RA, Stehouwer CD, Olthof CG, van Kamp GJ, Teerlink T, de Vries PM, Donker AJ. Plasma endothelin levels and vascular effects of intravenous L-arginine infusion in subjects with uncomplicated insulin dependent diabetes mellitus. Clin Science 1994; 87: 37-43.
58. Properzi G, Terenghi G, Gu XH, Poccia G, Pasqua R, Francavilla S, Polak JM. Early increase precedes a depletion of endothelin-1 but not of von Willebrand factor in cutaneous microvessels of diabetic patients. A quantitative immunohistochemistry study. J Pathol 1995; 175: 243-252.
59. Kirilov G, Dakovska L, Borisova AM, Krivoshiev S, Nentchev N. Increased plasma endothelin levels in patients with IDDM and end stage vascular complications. Hormone & Metabol Res 1994; 26: 119-120.
60. Patino R, Ibarra J, Molino A, Fernandez-Durango R, Moya J, Fernandez-Cruz A. Increased plasma endothelin in diabetes: an atherosclerosis marker? Diabetologia 1994; 37: 333-334.
61. Gruden G, Cavallo-Perin P, Bazzan M, Stella S, Vuolo A, Pagano G. PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria. Diabetes 1994; 43: 426-429.
62. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coag Fibrinolys 1992; 3: 439-449.
63. Sandset PM, Bendz B. Tissue factor pathway inhibitor: Clinical deficiency states. Thromb Haemost 1997; 78: 467-470.
64. Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: Potential therapeutic applications. Thromb Haemost 1997; 78: 471-477.
65. Yokoyama H, Myrup B, Rossing P, Ostergaard PB. Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy. Diabetes Care 1996; 19: 441-445.
66. Skrha J, Hodinar A, Kvasnicka J, Stibor V, Sperl M, Stolba P, Hilgertova J. Early changes of serum N-acetyl beta glucosaminidase, tissue plasminogen activator and erythrocyte Superoxide dismutase in relation to retinopathy in type 1 diabetes mellitus. Clin Chem Acta 1994; 229: 5-14.
67. de Bono D. Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease. Br Heart J 1994; 71: 504-507.
68. Hekman CM, Loskutoff DJ. Fibrinolytic pathways and the endothelium. Seminars Thromb Haemost 1987; 13: 514-527.
69. Erikson LA, Ginsberg MN, Loskutoff DJ. Detection and partial characterisation of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465-1472.
70. Wang DL, Pan YT, Wang JJ, Cheng CH, Liu CY. Demonstration of a functionally active tPA-like plasminogen activator in human platelets. Thromb Haemostas 1994; 71: 493-498.
71. Allen RA, Kluft C, Brommer EJP. The acute effect of smoking on fibrinolysis: increase in the activity level of circulating extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest 1984; 14: 354-361.
72. Lampeter ER, Hishimoto TK, Rothlein R, Mainolfi EA, Bertrams J, Kolb H, Martin S. Elevated levels of circulating adhesion molecules in IDDM patients and in subjects at risk for IDDM. Diabetes 1992; 41: 1668-1671.
73. DeLisser HM, Newman PJ, Albelda SM. Molecular and functional aspects of PECAM-1/CD31. Immunol Today 1994; 15: 490-495.
74. Blann AD, Wadley MS, Dobrotova M, Sanders P, Jayson MIV, McCollum CN. Soluble PECAM in inflammatory vascular disease, atherosclerotic vascular disease, and in cancer. Blood Coag Fibrin 1998; in press.
75. Schleiffenbaum B, Spertini O, Tedder TF. Soluble L-selectin is present in human plasma at high levels and retains functional activity. J Cell Biol 1992; 119: 229-238.
76. Saika T, Aoki N. Studies of plasma ECMR-III (CD44) and PECAM-1 (CD31) levels in diabetic patients (Abstract). Diabetologia 1997; 40 (suppl 1): A401.
77. Jang Y, Lincoff AM, Plow EF, Topol EJ. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994; 24: 1591-1601.
78. Kansas GS. Selectins and their ligands: current components and controversies. Blood 1996; 88: 3259-3287.
79. Frenette PS, Wagner DD. Adhesion molecules. New Engl J Med 1996; 334: 1526-1529 and 335: 43-45.
80. Frenette PS, Wagner DD. Adhesion molecules. New Engl J Med 1996; 334: 1526-1529 and 335: 43-45.
81. van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J Mol Med 1996; 74: 13-33.
82. Roep BO, Heidenthal E, de Vries RRP, Kolb H, Martin S. Soluble forms of intercellular adhesion molecule-1 in IDDM. Lancet 1994; 343: 1590-1593.
83. Uchikoshi F, Ito T, Kamiike W, Moriguchi A, Nozaki S, Ito A, et al. Anti-ICAM/LFA-1 monoclonal antibody therapy prevents graft rejection and IDDM recurrence in BB rat pancreas transplantation. Transpl Proc 1995; 27: 1527-1528.
84. Yagi N, Yokono K, Amano K, Nagata M, Tsukamoto K, Hasegawa Y, et al. Expression of intercellular adhesion molecule 1 on pancreatic beta cells accelerates beta cell destruction by cytotoxic t cells in murine autoimmune disease. Diabetes 1995; 44: 744-752.
85. Accardo-Palumbo A, Triolo G, Giardina E, Carbone MC, Ferrante A, Triolo G. Detection of anti-myeloperoxidase antibodies in the serum of patients with type 1 diabetes mellitus. Acta Diabetol 1996; 33: 103-107.
86. Esser P, Bresgen M, Fischbach R, Heimann K, Wiedemann P. Intercellular adhesion molecule-1 in plasma and vitreous from patients with vitreoretinal disorders. German J Ophthalmol 1995; 4: 269-274.
87. Tsukamoto K, Yokono K, Amano K, Nagata M, Yagi N, Tominaga Y, et al. Cell Immunol 1995; 165: 193-201.
88. Abeygunaratne R, Jude E, Young MJ, Bennett J, Abott C, Boulton AJM, Douglas JT. Cellular adhesion molecules in diabetes mellitus: ICAM-1 is a predictor of vascular complications (Abstract). Thromb Haemostas 1997; 143 (suppl).
89. Shaw S, Pegrum GD, Wolff S, Ashton WL. Platelet adhesiveness in diabetes mellitus. J Clin Path 1967; 20: 845-847.
90. Colwell JA, Lopes-Virella MF. A review of the development of large vessel disease in diabetes mellitus. Am J Med 1988; 85 (suppl 5A): 113-118.
91. Patrick AW, Oliver MD, Howie AF, Dawes J, Macintyre CC, Frier BM. Urinary excretion of beta thromboglobulin and N-acetyl beta-d-glucosaminidase in type 1 diabetes: potential indicators or early nephropathy? Diabetes Metabol 1990; 16: 441-447.
92. Vicari AM, Macagni A. Primary platelet activation in recent onset type 1 diabetes mellitus. Scand J Clin Lab Invest 1990; 50: 429-432.
93. Tschoepe D, Ostermann H, Huebinger A, Ziegler D, Wiefels K, Gries FA. Elevated platelet activation in type 1 diabetes with chronic complications under long-term near-normoglycaemic control. Haemostasis 1990; 20: 93-98.
94. Rak K, Beck P, Udvardy M, Pfliegler G, Misz M, Boda Z. Plasma levels of beta thromboglobulin and factor VIII related antigen in diabetic children and adults. Thromb Res 1983; 29: 155-162.
95. Bayraktar M, Dundar S, Kirazli S, Teletar F. Platelet factor 4, beta thromboglobulin and thrombospondin levels in type 1 diabetes mellitus patients. J Int Med Res 1994; 22: 90-94.
96. Huszka M, Kaplar M, Rejto L, Tornai I, Palatka K, Laszlo P, Udvardy M. The association of reducing endothelium derived relaxing factor-NO production with endothelial damage and increased in vivo platelet activation in patients with diabetes mellitus. Thromb Res 1997; 86: 173-180.
97. Palumbo PJ, O'Fallon WM, Osmundson PJ, Zimmerman BR, Langworthy AL, Kazmier FJ. Progression of peripheral occlusive arterial disease in diabetes mellitus. What factors are predictive? Arch Intern Med 1991; 151: 717-721.
98. Fijnheer R, Frijns CJM, Korteweg J, Rommes H, Peters JH, Sixma JJ, Nieuwenhuis HK. The origin of P-selectin as a circulating plasma protein. Thromb Haemostas 1997; 77: 1081-1085.
99. Blann AD, Lip GYH. Hypothesis: is soluble P-selectin a marker of platelet activation? Atherosclerosis 1997; 128: 135-138.
100. Blann AD, Lip GYH, Beevers DG, McCollum CN. Soluble P-selectin: a comparison with platelet and endothelial cell markers. Thromb Haemostas 1997; 77: 1077-1080.
101. Jilma B, Fasching P, Ruthner C, Rumplmayr A, Ruzicka S, Kapiotis S, et al. Elevated circulating P-selectin in insulin dependent diabetes mellitus. Thromb Haemost 1996; 76: 328-332.
102. Rauch U, Schwippert B, Schultheiss HP, Tschoepe D. Platelet activation is dependent on microangiopathic complications in insulin dependent diabetes mellitus (Abstract). Thromb Haemostas 1997; (suppl): 323.
103. Tschoepe D, Driesch E, Schwippert B, Lampeter EF. Activated platelets in subjects at increased risk of IDDM. DENIS Study Group. Diabetologia 1997; 40: 573-577.
104. Schror K. Blood vessel wall interaction in diabetes. Diabetes 1997; 46 (suppl 2): S115-S118.
105. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium dependent vasodilation in patients with insulin dependent diabetes mellitus. Circulation 1993; 88: 2510-2516.
106. Barnett AH. Pathogenesis of diabetic microangiopathy: an overview. Am J Med 1991; 90 (suppl 6A): 67s-73s.
107. Stehouwer CDA, Lambert J, Donker AJM, van Hinsbergh VMW. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997; 34: 55-68.
108. Gerrity RG, Antonov AS. The pathogenesis of atherosclerosis. Diabetologia 1997; 40: S108-S110.